Dose escalation completed in IAM1363-01 Ph 1/1b trial of IAM1363 in patients with HER2-altered cancers & brain mets / HER2 TKD mutation / HER2-amplified NSCLC June 10, 2025
Ph 1/2 trial of AVZO-023 initiated in patients with advanced or metastatic HR+/HER2- breast cancer and select other advanced solid tumors June 10, 2025
First Patient Enrolled in New Ph 2 Clinical Trial Protocol of Stenoparib in Advanced Ovarian Cancer June 3, 2025
First Patient Dosed in TNG456 Ph 1/2 Trial in Patients With MTAP-deleted GBM and Other Solid Tumors May 27, 2025
Monotherapy and combo arms of BBI-355 in POTENTIATE trial to be discontinued; BBI-355 – BBI-825 combo to be investigated May 27, 2025
IDeate-Esophageal01 Ph 3 Trial of Ifinatamab Deruxtecan Initiated in Certain Patients With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma May 21, 2025
Successful End of Ph 2 Meeting with US FDA on Ph 3 Registrational Study Design for PT-112 in Patients with Metastatic CRPC Announced May 21, 2025
GTB-3650 Ph 1 Trial Advanced to Cohort 2 Following Successful Initial Human Dosing and Evidence of Early Immune Activation Signals May 21, 2025
Ph 2 Trial evaluating the efficacy and safety of Lutetium (177Lu) rhPSMA-10.1 Injection initiated in metastatic CRPC May 13, 2025
First Patient Dosed in STARt-002 Trial of Invikafusp Alfa in Combination with Trodelvy® in Metastatic Breast Cancer May 13, 2025
First patient dosed in the randomized Ph 1/2 study of roginolisib in combination with dostarlimab with or without docetaxel, in advanced NSCLC patients May 13, 2025
Next phase of clinical development for cemsidomide to be enabled with new studies expected to initiate in early 2026 May 13, 2025
Plans for Ph 3 1L vepdegestrant combo trial with atirmociclib and Ph 3 2L combination trial with a CDK4/6 inhibitor shelved May 6, 2025
CAPItello-280 Ph 3 trial of Truqap (capivasertib) + docetaxel and ADT in patients with metastatic CRPC to be discontinued May 6, 2025
